Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.
Wessells H, Fuciarelli K, Hansen J et al. · The Journal of urology · PMID 9679884
Study summary
Main finding
The experiment recorded more erectile responses with Melanotan II than placebo. Nausea, yawning, stretching, and reduced appetite were reported more often after Melanotan II.
Ten men with psychogenic erectile dysfunction entered a double-blind, placebo-controlled crossover experiment. A crossover design compares study conditions within the same participants.
What the researchers measured
The presence, duration, and rigidity of erections were recorded with RigiScan monitoring over six hours. Adverse effects were also recorded.
How to read this evidence
The paper includes research in people. Its comparison groups, participant selection, follow-up, and measured outcomes determine how far the findings can be applied. The label alone does not establish efficacy or safety.
Results in context
Erectile responses were reported in eight of ten men after Melanotan II. Nausea, yawning, stretching, and reduced appetite were more frequent than after placebo. Short laboratory monitoring does not describe longer-term use or outcomes in other populations.
What this does not establish
Ten participants and brief laboratory monitoring cannot establish broader efficacy, uncommon harms, or long-term safety.
Publication & source
Why this paper is included
A placebo-controlled crossover study administered melanotan II to men with psychogenic erectile dysfunction.
Publication indexing
Clinical Trial · Comparative Study · Controlled Clinical Trial · Journal Article · Research Support, U.S. Gov't, P.H.S.